GENPET: Targeted FCH-PET imaging based on genetic profile
Research type
Research Study
Full title
Detection of metastatic disease in BRCA mutation carrier prostate cancer patients with optimised imaging protocols
IRAS ID
138894
Contact name
Rosalind Eeles
Contact email
Sponsor organisation
The Institute of Cancer Research/The Royal Marsden Hospital
Research summary
BRCA mutation carriers with prostate cancer have a higher incidence of metastatic disease and a worse prognosis compared to matched non BRCA carrier groups. Based on published data, all BRCA carriers diagnosed with prostate cancer are considered high risk, regardless of their NCCN classification.
This is a prospective study assessing the value of FCH-PET as a one-stop staging investigation for patients with germline BRCA mutations diagnosed with prostate cancer and comparing it to the standard staging investigations including MRI and bone scan. BRCA mutation carriers diagnosed with prostate cancer will be divided into 2 groups based on the NCCN risk classification. The first group will include the intermediate and high risk patients and the second group will include the low risk patients. Both groups will undergo staging with the standard combination of MRI pelvis and Bone scan, but patients will also undergo staging with an FCH-PET.
REC name
London - Fulham Research Ethics Committee
REC reference
14/LO/1628
Date of REC Opinion
24 Sep 2014
REC opinion
Unfavourable Opinion